In this article
FDA Accelerated Approval for Hepatocellular Carcinoma
Approval accelerated approval of pembrolizumab (Keytruda, Merck) for the treatment of patients with hepatocellular carcinoma (HCC) who had previously received sorafenib (Nexavar, Bayer). Keytruda is also approved in combination with carboplatin and paclitaxel or nab-paclitaxel for first-line treatment of metastatic squamous non-small cell lung cancer.
KEYNOTE-224 Trial Design and Efficacy Outcomes
FDA is based on single-arm, open label KEYNOTE-224 test results. The trial included 104 patients (median age, 68 years; 83% males; 81% whites; 14% Asians) with HCC who experienced disease progression or against Intolerance. The ECOG performance status of all patients was 0 (61%) or 1 (39%), which was Child-Pugh grade A liver function impairment. In addition, 21% were seropositive for hepatitis B virus, 25% were seropositive for hepatitis C virus, and 9% were seropositive. 64% of patients have extrahepatic disease, 17% have vascular invasion, and 9% have both. Patients received pembrolizumab 200 mg every 3 weeks for 24 months, or until disease progression or unacceptable toxicity. Objective response rate and duration of response were used as the main efficacy results. The median exposure time of pembrolizumab was 4.2 months. The ORR reported by the researchers was 17% (95% CI, 11-26), including a 1% complete response rate and a 16% partial response rate. Of the 18 patients who obtained the response, 16 (89%) were still effective for at least 6 months, and 10 (56%) were still effective for at least 12 months.
Safety Profile and Adverse Events
The adverse effects of Pembrolizumab-treated HCC patients appeared to be similar to those observed in other studies of melanoma or NSCLC, but the incidence of ascites increased (grade 3/4, 8%) and immune-mediated hepatitis (2.9%). Grade 3 or 4 laboratory abnormalities that occurred more frequently in the KEYNOTE-224 trial included elevated alanine aminotransferase (20%), elevated aspartate aminotransferase (9%) and hyperbilirubinemia (10 %).
Keytruda’s approval provides a new treatment option for patients with hepatocellular carcinoma who have received sorafenib treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.